Abstract: The image processing device comprises: a storage section storing a three-dimensional shape model in which feature amounts and three-dimensional positional information, for multiple feature points of a target object, are associated; an extraction process section configured to extract the feature amounts and two-dimensional positional information of the feature points from a two-dimensional image of the target object captured with a camera; and a recognition process section configured to identify three-dimensional positional information of the feature points of the two-dimensional image and recognize the position and orientation of the target object by matching the feature points of the two-dimensional image with the feature points of the three-dimensional model using the feature amounts.

Abstract: Provided is an information processing device and an information processing method that enable simple and appropriate calibration. When a pen-type device incorporating an inertial measurement unit such as an IMU is moved and a drawn image corresponding to a track is displayed, calibration is implemented on the basis of a measurement value of the inertial measurement device in one stationary attitude and a latitude and an absolute azimuth of the inertial measurement device at that time when the pen-type device is inserted into a pen stand to be fixed in a predetermined direction.

Abstract: A vertical layer stack including a bit-line-level dielectric layer and an etch stop dielectric layer can be formed over an array region. Bit-line trenches are formed through the vertical layer stack. Bit-line-trench fill structures are formed in the bit-line trenches. Each of the bit-line-trench fill structures includes a stack of a bit line and a capping dielectric strip. At least one via-level dielectric layer can be formed over the vertical layer stack. A bit-line-contact via cavity can be formed through the at least one via-level dielectric layer and one of the capping dielectric strips. A bit-line-contact via structure formed in the bit-line-contact via cavity includes a stepped bottom surface including a top surface of one of the bit lines, a sidewall segment of the etch stop dielectric layer, and a segment of a top surface of the etch stop dielectric layer.

Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

Abstract: It is an object of the present invention to provide an anti-GPR20 antibody that can be used in the detection of GPR20, a reagent for GPR20 detection comprising the antibody, a reagent for diagnosis or a composition for testing of a disease related to the expression of GPR20, etc. The present invention provides an antibody specifically binding to a peptide comprising the amino acid sequence at amino acid positions 1 to 48 in SEQ ID NO: 1, or an antigen-binding fragment of the antibody, a chimeric antibody of the antibody, a rabbit type antibody of the antibody, etc. The present invention also provides a composition comprising the antibody, etc.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

Abstract: A display apparatus includes a display surface, a plurality of microphones, each being arranged on each of peripheral sides of the display surface, and an orientation detecting sensor configured to detect orientation of the display surface. Each of the plurality of microphones is arranged so as not to be aligned with respect to other microphones arrayed on other sides in a first direction along one side of the display surface and a second direction orthogonal to the first direction. The display apparatus further includes circuitry configured to set an order of arrangement of the plurality of microphones in a horizontal direction based on a result obtained by the orientation detecting sensor.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: It is an object of the present invention to provide an anti-GPR20 antibody that can be used in the detection of GPR20, a reagent for GPR20 detection comprising the antibody, a reagent for diagnosis or a composition for testing of a disease related to the expression of GPR20, etc. The present invention provides an antibody specifically binding to a peptide comprising the amino acid sequence at amino acid positions 1 to 48 in SEQ ID NO: 1, or an antigen-binding fragment of the antibody, a chimeric antibody of the antibody, a rabbit type antibody of the antibody, etc. The present invention also provides a composition comprising the antibody, etc.

Abstract: A display apparatus includes a display surface, a plurality of microphones, each being arranged on each of peripheral sides of the display surface, and an orientation detecting sensor configured to detect orientation of the display surface. Each of the plurality of microphones is arranged so as not to be aligned with respect to other microphones arrayed on other sides in a first direction along one side of the display surface and a second direction orthogonal to the first direction. The display apparatus further includes circuitry configured to set an order of arrangement of the plurality of microphones in a horizontal direction based on a result obtained by the orientation detecting sensor.

Abstract: An engine (2) of a hybrid vehicle (1) is configured to operate along a prescribed operation line in an operation property diagram of the engine. In addition to a first operation line (A) that optimizes fuel economy, a second operation line (B) that minimizes undesired emission of particulate matter is defined. The two operation lines substantially coincide with each other in a certain region of the diagram. A control unit (7) of the vehicle switches the operating condition between the first operation line and the second operation line when the first operation line and the second operation line substantially coincide with each other.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: An engine (2) of a hybrid vehicle (1) is configured to operate along a prescribed operation line in an operation property diagram of the engine. In addition to a first operation line (A) that optimizes fuel economy, a second operation line (B) that minimizes undesired emission of particulate matter is defined. The two operation lines substantially coincide with each other in a certain region of the diagram. A control unit (7) of the vehicle switches the operating condition between the first operation line and the second operation line when the first operation line and the second operation line substantially coincide with each other.

Abstract: An abnormality determination device which is capable of shortening a time period required for performing abnormality determination of a plurality of devices, in a state in which the supply of evaporated fuel to an intake system is stopped, as a whole, thereby making it possible to increase the frequency of execution of the determination, and improve the throughput of an evaporated fuel processor for processing evaporated fuel. When first and second execution conditions are satisfied, respectively, first and second determination operations for determining the abnormalities of first and second devices, respectively, are performed in the state in which the supply of evaporated fuel is stopped. In a case where the first determination operation is completed, when the second execution condition has been satisfied, the second determination operation is started with the supply of evaporated fuel being held in the stopped state.